Literature DB >> 10759100

Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII.

A J Vlot1, E Ton, A J Mackaay, M H Kramer, C A Gaillard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759100     DOI: 10.1016/s0002-9343(99)00398-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  6 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 2.  Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.

Authors:  Robert J Porte; Frank W G Leebeek
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia.

Authors:  Henk R van Buuren; Jenne J Wielenga
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

4.  Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.

Authors:  Jean-Louis Vincent; Rolf Rossaint; Bruno Riou; Yves Ozier; David Zideman; Donat R Spahn
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

5.  Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report.

Authors:  Konstantinos Vlachos; Fotis Archontovasilis; Artemisia Papadima; Dimitrios Maragiannis; Stavros Aloizos; Emmanuel Lagoudianakis; Ioannis G Dalianoudis; Nikolaos Koronakis; John Chrysikos; Spyros Zaravinos; Andreas Manouras
Journal:  Cases J       Date:  2008-11-29

Review 6.  Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.

Authors:  Christian von Heymann; Sven Jonas; Claudia Spies; Klaus-Dieter Wernecke; Sabine Ziemer; Detlev Janssen; Jürgen Koscielny
Journal:  Crit Care       Date:  2008-02-15       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.